United States Insulin Delivery Market Outlook to 2022

GlobalData
153 Pages - GLDATA57670
$4,995.00

Summary

GlobalData’s new report, "United States Insulin Delivery Market Outlook to 2022", provides key market data on the United States Insulin Delivery market. The report provides value, in millions of US dollars, volume (in units) and average prices (USD) within market segments - Insulin Pens, Insulin Pumps, Insulin Syringes and Traditional Insulin Pump Accessories.

The report also provides company shares and distribution shares data for each of these market segements, and global corporate-level profiles of the key market participants. Based on the availability of data for the particular market and country, information related to pipeline products, news and deals is available in the report.

Extensive interviews are conducted with key opinion leaders (KOLs), physicians and industry experts to validate the market size, company share and distribution share data and analysis.

Scope

- Market size and company share data for Insulin Delivery market segments - Insulin Pens, Insulin Pumps, Insulin Syringes and Traditional Insulin Pump Accessories.
- Annualized market revenues (USD million) and volume (units) data for each of the market segements. Data is provided from 2008 to 2015 and forecast to 2022.
- 2015 company shares and distribution shares data for each of the market segements.
- Global corporate-level profiles of key companies operating within the United States Insulin Delivery market.
- Key players covered include Medtronic plc, Becton Dickinson and Co, Eli Lilly and Company, Novo Nordisk A/S and Others.

Reasons to buy

- Develop business strategies by identifying the key market segments poised for strong growth in the future.
- Develop market-entry and market expansion strategies.
- Design competition strategies by identifying who-stands-where in the market.
- Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.
- What are the key distribution channels and what’s the most preferred mode of product distribution - Identify, understand and capitalize.

Companies Mentioned

Medtronic plc
Eli Lilly and Company
Becton Dickinson and Co
Novo Nordisk A/S
Insulet Corp
Sanofi
Tandem Diabetes Care, Inc.
F. Hoffmann-La Roche Ltd
B. Braun Melsungen AG

'

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 6
1.2 List of Figures 7
2 Introduction 8
2.1 What Is This Report About? 8
2.2 Insulin Delivery Market Segmentation 8
2.3 Definitions of Markets Covered in the Report 9
3 Insulin Delivery Market, United States 11
3.1 Insulin Delivery Market, United States, Revenue ($m), 2008-2015 11
3.2 Insulin Delivery Market, United States, Revenue ($m), 2015-2022 13
3.2.1 Insulin Pens Market, United States, Revenue ($m), by Segment, 2008-2015 15
3.2.2 Insulin Pumps Market, United States, Revenue ($m), by Segment, 2008-2015 17
3.2.3 Insulin Pens Market, United States, Revenue ($m), by Segment, 2015-2022 19
3.2.4 Insulin Pumps Market, United States, Revenue ($m), by Segment, 2015-2022 21
3.3 Insulin Delivery Market, United States, Volume (Units), 2008-2015 23
3.4 Insulin Delivery Market, United States, Volume (Units), 2015-2022 25
3.4.1 Insulin Pens Market, United States, Volume (Units), by Segment, 2008-2015 27
3.4.2 Insulin Pumps Market, United States, Volume (Units), by Segment, 2008-2015 29
3.4.3 Insulin Pens Market, United States, Volume (Units), by Segment, 2015-2022 31
3.4.4 Insulin Pumps Market, United States, Volume (Units), by Segment, 2015-2022 33
3.5 Insulin Delivery Market, United States, Average Price ($), 2008-2022 35
3.6 Insulin Delivery Market, United States, Distribution Share by Revenue ($m), 2014-2015 37
3.7 Insulin Delivery Market, United States, Company Share by Revenue ($m), 2015 38
4 Overview of Key Companies in United States, Insulin Delivery Market 40
4.1 Medtronic plc 40
4.1.1 Company Overview 40
4.2 Eli Lilly and Company 40
4.2.1 Company Overview 40
4.3 Becton Dickinson and Co 40
4.3.1 Company Overview 40
4.4 Novo Nordisk A/S 41
4.4.1 Company Overview 41
4.5 Insulet Corp 41
4.5.1 Company Overview 41
4.6 Sanofi 41
4.6.1 Company Overview 41
4.7 Tandem Diabetes Care, Inc. 41
4.7.1 Company Overview 41
4.8 F. Hoffmann-La Roche Ltd 42
4.8.1 Company Overview 42
4.9 B. Braun Melsungen AG 42
4.9.1 Company Overview 42
5 Insulin Delivery Market Pipeline Products 43
6 Financial Deals Landscape 44
6.1 Acquisition 44
6.1.1 MannKind May Sell Itself 44
6.2 Debt Offerings 45
6.2.1 Becton Dickinson Prices Public Offering of 1% Notes Due 2022 for USD500 Million 45
6.2.2 Becton Dickinson Prices Public Offering of 1.9% Notes Due 2026 for USD500 Million 47
6.2.3 Insulet Raises Private Placement of Senior Notes for USD300 Million 49
6.3 Equity Offerings 50
6.3.1 ConvaTec Raises USD1.8 Billion in IPO 50
6.3.2 Mannkind Prices Shares Issue for USD50 Million 52
6.3.3 Valeritas Raises USD25 Million in Private Placement of Shares 53
6.4 Partnerships 54
6.4.1 Becton, Dickinson Enters into Research Agreement with Juvenile Diabetes Research Foundation 54
6.4.2 Metabolon Enters into Licensing Agreement with Synlab 55
6.5 Venture Financing 56
6.5.1 Dance Biopharm Raises USD0.625 Million in Venture Financing 56
7 Recent Developments 57
7.1 Corporate Communications 57
7.1.1 Nov 30, 2016: Valeritas Elects Joe Mandato, Ph.D., Experienced Medical Device Executive and Investor, to Board of Directors 57
7.1.2 Oct 31, 2016: Antares Pharma Appoints Fred M. Powell, Senior Vice President and Chief Financial Officer 57
7.1.3 Oct 05, 2016: Henry Ford Health System Announces New CEO of Health Alliance Plan 58
7.1.4 Sep 22, 2016: Industry Veteran Katherine D. Crothall, PhD to Join Valeritas Board of Directors 58
7.1.5 Sep 14, 2016: Levi Garraway, M.D., Ph.D., to become Senior Vice President of Global Oncology at Lilly, Succeeding Richard Gaynor, M.D., Who is Retiring after a Distinguished Career 59
7.1.6 Sep 06, 2016: Insulet Announces Executive Appointments 60
7.1.7 Aug 31, 2016: Jamere Jackson Elected To Lilly Board Of Directors 60
7.1.8 Aug 16, 2016: Valeritas Appoints Erick J. Lucera as Chief Financial Officer 61
7.1.9 Aug 10, 2016: Lilly announces Joshua Smiley, Anat Ashkenazi appointed to new roles, Thomas Grein retires 62
7.1.10 Jul 28, 2016: BD Names R. Andrew Eckert To Board Of Directors 62
7.1.11 Jul 27, 2016: John C. Lechleiter to Retire as Lilly CEO; Board Elects David A. Ricks as Successor 63
7.1.12 Jul 13, 2016: Valeritas Appoints Brian K. Roberts to its Board of Directors 64
7.1.13 Jun 27, 2016: ConvaTec Provides Business Updates 65
7.1.14 Jun 23, 2016: Valeritas Appoints David Lewis as Vice President of Marketing 65
7.1.15 Jun 22, 2016: Johnson & Johnson Announces Retirement of Louise Mehrotra and Appointment of Joseph Wolk as Vice President of Investor Relations 65
7.1.16 Jun 13, 2016: Aarti Shah named chief information officer 66
7.1.17 Jun 02, 2016: Nektar Therapeutics Announces Executive Management Promotions 67
7.1.18 Apr 25, 2016: Peter J. Devlin Joins Valeritas Board of Directors as Independent Director 68
7.1.19 Apr 19, 2016: Rodney D. Altman, MD Joins Valeritas Board of Directors 68
7.1.20 Apr 08, 2016: Dr. Henry Anhalt to Step Down From Tandem Diabetes Care Board of Directors to Ensure No Risk of Potential Conflict of Interest 69
7.1.21 Mar 16, 2016: Insulet Names Aiman Abdel-Malek, Ph.D. Senior Vice President of Advanced Technology and Engineering 69
7.1.22 Mar 14, 2016: Tandem Diabetes Care Announces Appointment of Dr. Henry Anhalt as Board Member 70
7.1.23 Mar 14, 2016: MannKind Announces Appointment of Michael Castagna as Chief Commercial Officer 70
7.1.24 Mar 02, 2016: Insulet Announces Organizational Enhancements 71
7.1.25 Feb 25, 2016: Valeritas Announces Leadership and Board of Directors Changes 72
7.1.26 Feb 09, 2016: Insulet Appoints David A. Lemoine to Board of Directors 73
7.1.27 Feb 02, 2016: Tandem Diabetes Care Expands Commercial Leadership 73
7.1.28 Jan 26, 2016: Antares Pharma Announces CEO Transition 74
7.1.29 Jan 19, 2016: Johnson & Johnson Announces Actions To Strengthen Medical Devices Leadership Position In Evolving Healthcare Marketplace 74
7.1.30 Dec 23, 2015: MannKind Announces Appointment of Duane DeSisto as Chief Executive Officer 75
7.2 Financial Announcements 76
7.2.1 Nov 14, 2016: Retractable Technologies Reports Results as of September 30, 2016 76
7.2.2 Nov 10, 2016: Valeritas Reports Third Quarter 2016 Financial Results 77
7.2.3 Nov 09, 2016: Antares Pharma Reports Third Quarter 2016 Financial and Operating Results 78
7.2.4 Nov 09, 2016: Aradigm Announces Third Quarter 2016 Financial Results 80
7.2.5 Nov 09, 2016: MannKind Reports 2016 Third Quarter Financial Results 81
7.2.6 Nov 03, 2016: Nektar Therapeutics Reports Financial Results for the Third Quarter of 2016 82
7.2.7 Nov 03, 2016: BD Announces Results For 2016 Fourth Fiscal Quarter And Full Year; Provides Fiscal 2017 Guidance 84
7.2.8 Nov 03, 2016: Insulet Reports Third Quarter 2016 Financial Results 86
7.2.9 Nov 01, 2016: Tandem Diabetes Care Reports Third Quarter 2016 Financial Results 87
7.2.10 Oct 25, 2016: Lilly Reports Third-Quarter 2016 Results 88
7.2.11 Oct 18, 2016: Johnson & Johnson Reports 2016 Third-Quarter Results 93
7.2.12 Aug 16, 2016: Retractable Technologies Reports Results as of June 30, 2016 95
7.2.13 Aug 10, 2016: Aradigm Announces Second Quarter 2016 Financial Results 96
7.2.14 Aug 10, 2016: Valeritas Reports Second Quarter 2016 Financial Results 97
7.2.15 Aug 09, 2016: Antares Pharma Reports Second Quarter 2016 Operating and Financial Results 98
7.2.16 Aug 08, 2016: MannKind Reports 2016 Second Quarter Financial Results 100
7.2.17 Aug 04, 2016: BD Announces Results For 2016 Third Fiscal Quarter 101
7.2.18 Aug 03, 2016: Nektar Therapeutics Reports Financial Results for the Second Quarter of 2016 103
7.2.19 Aug 03, 2016: Insulet Reports Second Quarter 2016 Financial Results 104
7.2.20 Jul 28, 2016: Integer Holdings Reports 2016 Second Quarter Results 105
7.2.21 Jul 26, 2016: Lilly Reports Second-Quarter 2016 Results, Provides Financial Expectations Through The Remainder Of The Decade 108
7.2.22 Jul 19, 2016: Johnson & Johnson Reports 2016 Second-Quarter Results 113
7.2.23 May 17, 2016: Retractable Technologies Reports Results for the First Quarter of 2016 115
7.2.24 May 10, 2016: Aradigm Announces First Quarter 2016 Financial Results 116
7.2.25 May 09, 2016: Antares Pharma Reports First Quarter 2016 Operating and Financial Results 117
7.2.26 May 09, 2016: MannKind Reports 2016 First Quarter Financial Results 118
7.2.27 May 03, 2016: Insulet Reaffirms Second Quarter and Full Year 2016 Guidance 119
7.2.28 Apr 28, 2016: Greatbatch Reports 2016 First Quarter Results 119
7.2.29 Apr 28, 2016: Tandem Diabetes Care Reports First Quarter 2016 Financial Results and Updates 2016 Guidance 122
7.2.30 Apr 28, 2016: Insulet Reports First Quarter 2016 Financial Results 123
7.2.31 Apr 19, 2016: Johnson & Johnson Reports 2016 First-Quarter Results 124
7.2.32 Apr 01, 2016: Retractable Technologies Reports Results for the Year 2015 125
7.2.33 Mar 08, 2016: Antares Pharma Reports Fourth Quarter and Full Year 2015 Operating and Financial Results 126
7.2.34 Feb 29, 2016: Greatbatch Reports 2015 Fourth Quarter and Full Year Results 128
7.2.35 Feb 25, 2016: Insulet Reports Fourth Quarter and Full Year 2015 Financial Results 131
7.2.36 Feb 24, 2016: Tandem Diabetes Care Reports Fourth Quarter and Full Year 2015 Financial Results 133
7.2.37 Jan 26, 2016: Johnson & Johnson Reports 2015 Fourth-Quarter Results 134
7.2.38 Jan 11, 2016: Greatbatch Provides Preliminary 2015 Revenue Results and 2016 Guidance 136
7.3 Legal And Regulatory 137
7.3.1 Dec 02, 2016: Retractable Technologies Reports on Fifth Circuit's Opinion 137
7.3.2 Nov 15, 2016: Henry Ford Radiation Oncology Receives 3-Year ACR Accreditation 137
7.3.3 Jun 30, 2016: NuVasive Agrees to Settle Patent Litigation With Medtronic 138
7.3.4 Jun 10, 2016: Insulet Partners with Joslin Diabetes Center to Implement a Unique Training Certification for Insulet's Clinical Team 138
7.3.5 Apr 18, 2016: Henry Ford Breast Cancer Program Granted 3-Year Accreditation 139
7.3.6 Mar 14, 2016: DECN Subsidiaries Sue Johnson & Johnson and Several Divisions for Patent Infringement 139
7.3.7 Feb 29, 2016: Baron & Budd Investigating Potential Lawsuits Against Johnson & Johnson Regarding Link Between Talcum Powder and Ovarian Cancer 140
7.4 Other Significant Developments 140
7.4.1 Dec 15, 2016: Lilly Provides 2017 Financial Guidance And 2016 Update, Reaffirms Financial Expectations Through The Remainder Of The Decade 140
7.4.2 Oct 05, 2016: T1D Exchange Initiates Multi-million Dollar Investment in Automated Insulin Delivery Technologies 142
7.4.3 Sep 06, 2016: Insulet to Establish Highly-Automated Manufacturing Operation in the United States 142
7.4.4 Jul 28, 2016: Tandem Diabetes Care Reports Second Quarter 2016 Financial Results 143
7.4.5 Jun 27, 2016: Greatbatch Renamed Integer Holdings 144
7.5 Strategy And Business Planning 145
7.5.1 Nov 22, 2016: Highly Pathogenic Bird Flu Spreading Across Europe and Asia; BiondVax’s Universal Flu Vaccine Candidate Also Covers these Potential Pandemic Strains 145
7.5.2 Apr 11, 2016: CeQur Initiates Significant Facility Expansion in Marlborough 146
7.5.3 Apr 05, 2016: Allegiance Health Joins Henry Ford Health System 147
7.5.4 Jan 25, 2016: AstraZeneca partners with peers and academia to establish translational research fund 148
8 Appendix 149
8.1 Research Methodology 150
8.1.1 Coverage 150
8.1.2 Secondary Research 150
8.1.3 Primary Research 151
8.1.4 Company Share Analysis 151
8.1.5 Distribution Share Analysis 151
8.1.6 Benchmarking 152
8.2 GlobalData Consulting 152
8.3 Contact Us 152
8.4 Disclaimer 153

1.1 List of Tables
Table 1: Insulin Delivery Market, United States, Revenue ($m), USD Constant, Historic, 2008-2015 12
Table 2: Insulin Delivery Market, United States, Revenue ($m), USD Constant, Forecast, 2015-2022 14
Table 3: Insulin Pens Market, United States, Revenue ($m), USD Constant, Historic, 2008-2015 16
Table 4: Insulin Pumps Market, United States, Revenue ($m), USD Constant, Historic, 2008-2015 18
Table 5: Insulin Pens Market, United States, Revenue ($m), USD Constant, Forecast, 2015-2022 20
Table 6: Insulin Pumps Market, United States, Revenue ($m), USD Constant, Forecast, 2015-2022 22
Table 7: Insulin Delivery Market, United States, Volume (Units), Historic, 2008-2015 24
Table 8: Insulin Delivery Market, United States, Volume (Units), Forecast, 2015-2022 26
Table 9: Insulin Pens Market, United States, Volume (Units), Historic, 2008-2015 28
Table 10: Insulin Pumps Market, United States, Volume (Units), Historic, 2008-2015 30
Table 11: Insulin Pens Market, United States, Volume (Units), Forecast, 2015-2022 32
Table 12: Insulin Pumps Market, United States, Volume (Units), Forecast, 2015-2022 34
Table 13: Insulin Delivery Market, United States, Average Price ($) Historic, 2008-2022 35
Table 14: Insulin Delivery Market, United States, Average Price ($), Forecast, 2015-2022 36
Table 15: Insulin Delivery Market, United States, Distribution Share by Revenue ($m), USD Constant, 2014-2015 37
Table 16: Insulin Delivery Market, United States, Company Share by Revenue ($m), USD Constant, 2015 39
Table 17: Insulin Delivery Market Pipeline Products 43
Table 18: MannKind May Sell Itself 44
Table 19: Becton Dickinson Prices Public Offering of 1% Notes Due 2022 for USD500 Million 45
Table 20: Becton Dickinson Prices Public Offering of 1.9% Notes Due 2026 for USD500 Million 47
Table 21: Insulet Raises Private Placement of Senior Notes for USD300 Million 49
Table 22: ConvaTec Raises USD1.8 Billion in IPO 50
Table 23: Mannkind Prices Shares Issue for USD50 Million 52
Table 24: Valeritas Raises USD25 Million in Private Placement of Shares 53
Table 25: Becton, Dickinson Enters into Research Agreement with Juvenile Diabetes Research Foundation 54
Table 26: Metabolon Enters into Licensing Agreement with Synlab 55
Table 27: Dance Biopharm Raises USD0.625 Million in Venture Financing 56

1.2 List of Figures
Figure 1: Insulin Delivery Market, United States, Revenue ($m), USD Constant, Historic, 2008-2015 11
Figure 2: Insulin Delivery Market, United States, Revenue ($m), USD Constant, Forecast, 2015-2022 13
Figure 3: Insulin Pens Market, United States, Revenue ($m), USD Constant, Historic, 2008-2015 15
Figure 4: Insulin Pumps Market, United States, Revenue ($m), USD Constant, Historic, 2008-2015 17
Figure 5: Insulin Pens Market, United States, Revenue ($m), USD Constant, Forecast, 2015-2022 19
Figure 6: Insulin Pumps Market, United States, Revenue ($m), USD Constant, Forecast, 2015-2022 21
Figure 7: Insulin Delivery Market, United States, Volume (Units), Historic, 2008-2015 23
Figure 8: Insulin Delivery Market, United States, Volume (Units), Forecast, 2015-2022 25
Figure 9: Insulin Pens Market, United States, Volume (Units), Historic, 2008-2015 27
Figure 10: Insulin Pumps Market, United States, Volume (Units), Historic, 2008-2015 29
Figure 11: Insulin Pens Market, United States, Volume (Units), Forecast, 2015-2022 31
Figure 12: Insulin Pumps Market, United States, Volume (Units), Forecast, 2015-2022 33
Figure 13: Insulin Delivery Market, United States, Company Share (%) 2015 38

$4,995.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

Please contact us at [email protected]
or +1 212 564 2838

 

Custom Research

Contact us to speak
with your industry analyst.

[email protected] 
+1 212 564 2838

 



Discount Codes

Request Discount Codes
for reports of interest to you.

[email protected]
+1 212 564 2838



Browse All Reports